.jpeg&w=3840&q=100)
Why Azelaic Acid Is the Do-It-All Skin-Clearing Ingredient You've Been Looking For
Azelaic acid is the unsung hero of exfoliants. While retinoids and chemical exfoliators like alpha-hydroxy and beta-hydroxy acids get plenty of well-deserved hype for their ability to renew skin, they're just not for everyone. If you've tried these ingredients and they weren't right for you, azelaic acid products should be on your radar. 'Despite having the word 'acid' in its name, azelaic acid is well-tolerated,' says board-certified dermatologist Dr. Evan Rieder.
Vogue's Favorite Azelaic Acid Products
Azelaic acid is not an AHA or BHA, but a dicarboxylic acid, and naturally occurs in grains. Yes, it gently resurfaces skin, which inherently helps smooth out uneven texture, fade dark spots, and unclog pores, but azelaic acid has other properties that enhance these benefits. The ingredient is an antioxidant and has potent anti-inflammatory effects, which is why it's long been used by dermatologists to treat redness, including the flushing associated with rosacea. It has antibacterial properties, too, and kills Cutibacterium acnes, the bacteria implicated in acne, says board-certified dermatologist Dr. Morayo Adisa. 'It also brightens skin by inhibiting tyrosinase, the enzyme responsible for melanin production, making it ideal for post-acne marks and melasma with a low risk of irritation,' adds board-certified dermatologist Dr. Anetta Reszko.
In This Article:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
6 minutes ago
- CBS News
Oakland children's hospital workers end strike after judge denies injunction
Employees at UCSF Benioff Children's Hospital in Oakland will be back at work on Monday after deciding to end their strike. According to the National Union of Healthcare Workers, a federal judge denied their request to stop UCSF Health from proceeding to cancel union contracts. The cancellation would turn Oakland Hospital Employees into direct UCSF employees, effective July 6. Jackie Patrick has worked at the hospital as a patient care assistant for 32 years and spent several days out on the picket line. "It was horrible to be striking because we would rather be inside taking care of our patients," said Patrick. They're going back, despite not getting what they wanted, but they know their patients need them. "I love the children because sometimes kids are so scared and it's a calming effect if you come into the room and you smile and hug them," Patrick said about the fulfilling opportunities her job provides. The union says they're still fighting in other ways after their request to stop UCSF Health from cancelling union contracts was denied. "How that impacts me personally is that they're changing our benefits," explained Patrick. "The benefits in our contracts are very good. We fought for a good contract. We'll have to contribute a percentage to our retirement, which our retirement is fully funded. We'll have to contribute a healthcare premium plus our co-pays, which we don't pay that now." Patrick says if they are converted to UCSF workers, some of her co-workers will make thousands of dollars less each years because of the changes to their benefits. The union believes the integration plan violates their contract with the hospital and a hearing is scheduled for July 17th. "At the next hearing, they'll decide if we have the right to go to arbitration, which we believe that we do because this is subcontracting," Patrick said. They're also seeking injunction relief from the National Labor Relations Board. In a statement from UCSF Health, they say this integration is to help with one goal: delivering even better care for Oakland's children. "This transition will improve care for our patients and families, who should not have to navigate two separate systems to get the services their children need. It will also provide employees with significantly expanded benefits and career opportunities. This transition is also critical to delivering on our $1.6 billion investment in UCSF Benioff Children's Hospital Oakland, which will strengthen the hospital's role as a leading center for pediatric care in the East Bay for decades to come." Some employees are considering early retirement because of the situation. But for Patrick, she's going to continue to fight for her contract while supporting their patients. "The community that we serve a lot of them are low-income, Medi-Cal patients," Patrick said. "We don't care who you are. You come to that door and we're going to see you, money or no money. We're going to love you, money or no money."
Associated Press
19 minutes ago
- Associated Press
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS
NEW YORK, June 30, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for clinical trials of KLTO-202, its investigational gene therapy for amyotrophic lateral sclerosis (ALS). A unique RNA splice variant of the human gene called alpha-Klotho has been licensed by the Company from the Autonomous University of Barcelona ('UAB') including patents, patent applications, research, knowhow and other intellectual properties for use in the development of advanced gene and gene-engineered cell therapies. The human alpha-Klotho gene is located in cells found throughout the human body. It is a five exon gene that produces two protein isoforms: a full-length protein found mainly in cells of the kidney called membrane-bound Klotho (or m-KL), which controls phosphate homeostasis, and a much smaller protein isoform called secreted alpha-Klotho (or s-KL). The s-KL RNA splice variant is found mainly in the brain and spinal cord neurons; the variant protein is neuroprotective by minimizing both oxidative stress and neuroinflammation. Animal studies supported by the Company over the past two years in mouse and non-human primate models of rapid aging, in models of human Alzheimer's disease, and in models of ALS have shown that over-expression and amplification of the tissue levels of s-KL using a gene therapy approach result in highly favorable therapeutic outcomes in every model tested. These results have been published in peer-reviewed scientific journals and now support the transition of KLTO-202 into the clinical development stage. The Company expects that it will take approximately eight months to complete process development and manufacturing of KLTO-202, and about four to six months to conduct meetings with FDA, complete all FDA-mandated animal safety studies, file an investigational new drug application (IND), train and prepare clinical sites where the Phase I/II studies can be conducted, and then begin the single-dose gene therapy studies in ALS patients by the third quarter of next year. The Company will work with contract research organizations (CROs) to facilitate all activities including manufacturing and clinical trials without the need to hire several dozen staff members, which would significantly increase our operating overhead. Dr. Joseph Sinkule, the Company's CEO and founder commented: 'With our recent fundraising success, we're moving forward with manufacturing the s-KL transgene DNA for KLTO-202. We've identified a more efficient method of producing the AAV vector to deliver the s-KL gene directly to motor neurons—the cells most affected by ALS. Our goal is to increase local s-KL protein levels to protect these neurons from the damage that leads to voluntary and involuntary muscle paralysis and ultimately death.' ALS typically progresses rapidly, with most patients losing mobility, respiratory function, and life within just 2–3 years of diagnosis. About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the 'anti-aging' human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The Company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization. Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFO [email protected] Website: Forward-Looking Statements: This press release contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words 'believe,' 'project,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'strategy,' 'future,' 'opportunity,' 'plan,' 'may,' 'should,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the 'SEC') from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. View original content to download multimedia: SOURCE Klotho Neurosciences, Inc.
Yahoo
24 minutes ago
- Yahoo
Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS
NEW YORK, June 30, 2025 /CNW/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) today announced that it is moving forward with manufacturing and process development work in preparation for clinical trials of KLTO-202, its investigational gene therapy for amyotrophic lateral sclerosis (ALS). A unique RNA splice variant of the human gene called alpha-Klotho has been licensed by the Company from the Autonomous University of Barcelona ("UAB") including patents, patent applications, research, knowhow and other intellectual properties for use in the development of advanced gene and gene-engineered cell therapies. The human alpha-Klotho gene is located in cells found throughout the human body. It is a five exon gene that produces two protein isoforms: a full-length protein found mainly in cells of the kidney called membrane-bound Klotho (or m-KL), which controls phosphate homeostasis, and a much smaller protein isoform called secreted alpha-Klotho (or s-KL). The s-KL RNA splice variant is found mainly in the brain and spinal cord neurons; the variant protein is neuroprotective by minimizing both oxidative stress and neuroinflammation. Animal studies supported by the Company over the past two years in mouse and non-human primate models of rapid aging, in models of human Alzheimer's disease, and in models of ALS have shown that over-expression and amplification of the tissue levels of s-KL using a gene therapy approach result in highly favorable therapeutic outcomes in every model tested. These results have been published in peer-reviewed scientific journals and now support the transition of KLTO-202 into the clinical development stage. The Company expects that it will take approximately eight months to complete process development and manufacturing of KLTO-202, and about four to six months to conduct meetings with FDA, complete all FDA-mandated animal safety studies, file an investigational new drug application (IND), train and prepare clinical sites where the Phase I/II studies can be conducted, and then begin the single-dose gene therapy studies in ALS patients by the third quarter of next year. The Company will work with contract research organizations (CROs) to facilitate all activities including manufacturing and clinical trials without the need to hire several dozen staff members, which would significantly increase our operating overhead. Dr. Joseph Sinkule, the Company's CEO and founder commented: "With our recent fundraising success, we're moving forward with manufacturing the s-KL transgene DNA for KLTO-202. We've identified a more efficient method of producing the AAV vector to deliver the s-KL gene directly to motor neurons—the cells most affected by ALS. Our goal is to increase local s-KL protein levels to protect these neurons from the damage that leads to voluntary and involuntary muscle paralysis and ultimately death." ALS typically progresses rapidly, with most patients losing mobility, respiratory function, and life within just 2–3 years of diagnosis. About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The Company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization. Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFOir@ Website: Forward-Looking Statements: This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. View original content to download multimedia: SOURCE Klotho Neurosciences, Inc. View original content to download multimedia: Sign in to access your portfolio
